Arbutus Biopharma
ABUS
ABUS
55 hedge funds and large institutions have $88.8M invested in Arbutus Biopharma in 2016 Q4 according to their latest regulatory filings, with 14 funds opening new positions, 23 increasing their positions, 12 reducing their positions, and 7 closing their positions.
New
Increased
Maintained
Reduced
Closed
more first-time investments, than exits
New positions opened: | Existing positions closed:
more repeat investments, than reductions
Existing positions increased: | Existing positions reduced:
more ownership
Funds ownership: →
more funds holding
Funds holding: →
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
23% less capital invested
Capital invested by funds: $115M → $88.8M (-$26.2M)
48% less call options, than puts
Call options by funds: $620K | Put options by funds: $1.19M
Holders
55
Holding in Top 10
1
Calls
$620K
Puts
$1.19M
Top Buyers
| 1 | +$13M | |
| 2 | +$1.32M | |
| 3 | +$824K | |
| 4 |
DCM
DAFNA Capital Management
Los Angeles,
California
|
+$573K |
| 5 |
OAM
Oxford Asset Management
Oxford,
United Kingdom
|
+$392K |
Top Sellers
| 1 | -$6.88M | |
| 2 | -$2.36M | |
| 3 | -$1.12M | |
| 4 |
SCM
Suffolk Capital Management
New York
|
-$1.08M |
| 5 |
B
Bailard
Foster City,
California
|
-$740K |